BioSpace News Archive

FY2020 Q3 Year-to-Date Results Driven by 15% Underlying Revenue Growth of 14 Global Brands (e.g., ENTYVIO +24.0%, TAKHZYRO +38.1%, Immunoglobulin +13.7%); Generated Strong Margins and Cash Flow

Evotec SE announced that the Company has entered into a multi-year partnership with the Medical Center Hamburg-Eppendorf for the development of a highly innovative first-in-class cell therapy approach for the treatment of heart failure.

Quest Diagnostics Incorporated (NYSE: DGX), the world’s leading provider of diagnostic information services, announced today the Company’s Board of Directors has authorized a 10.7% increase in its quarterly dividend from $0.56 to $0.62 per share.

ChromaDex Corp. (NASDAQ: CDXC) today announced results from the study “Combined Metabolic Cofactor Supplementation Reduces Liver Fat in Nonalcoholic Fatty Liver Disease” were published on Cell Press Sneak Peek, a preprint publication website for papers under review by Cell Press Journals

Kenneth C. Frazier to Retire as Merck CEO; Board Elects Robert M. Davis as Successor; Frazier to Continue as Executive Chairman

Bristol-Myers Squibb Company (NYSE:BMY) (“Bristol Myers Squibb”), with its wholly-owned subsidiary Celgene Corporation (“Celgene”) (collectively, the “Offerors”), announced the commencement of 20 separate offers to purchase for cash notes issued by the Offerors listed in the tables below (collectively, the “Notes”) for an aggregate purchase price of up to $4.0 billion.

Koya Medical (www.koyamedical.com), a healthcare company focused on developing breakthrough treatments for lymphedema and venous disorders, announced the appointment of Stanley G. Rockson, MD as its Chief Medical Officer.

- Fourth quarter revenues of $3.0 billion, up 55.8% versus 2019 - Fourth quarter diluted earnings per share from continuing operations of $4.21, up 126.9% from 2019; and adjusted diluted EPS of $4.48, up 167.7% from 2019 - Full year revenues of $9.44 billion, up 22.1% from 2019 - Full year diluted EPS of $10.47, up 70.8% from 2019; and adjusted diluted EPS of $11.18, up 70.4% from 2019

Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced it will participate in two investor conferences in February. Karen Zaderej, chairman, CEO, and president, will participate in a fireside chat at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Thursday, February 18, 2021 at 9:00 a.m

TELA Bio, Inc. (“TELA”), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced that the Company will participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference.